China is a country with a high incidence of liver cancer, and the underlying reason is that the rate of chronic hepatitis B virus infection among Chinese people is much higher than that in Europe and the United States, and hepatitis B virus happens to be the main cause (not one of them) of liver cancer. A survey has been done and among liver cancer patients, the rate of positive hepatitis B virus surface antigen is over 95%! To make matters worse, liver cancer again occurs mostly in patients with cirrhosis, which in turn is the end result of long-term hepatitis B virus infection. The results of a bulk epidemiological study conducted by Taiwanese scholars show that chronic hepatitis B virus-infected patients over 30 years of age with normal transaminases who have a viral gene level greater than 6 times 10 per milliliter in their blood have a more than 35% chance of developing cirrhosis and nearly 15% chance of developing liver cancer within 13 years! These data not only indicate that hepatitis B virus is the direct cause of hepatitis B, but also indirectly suggest that once liver cancer occurs, it is important to “mend the fold”. Although the results reported by various researchers are inconsistent, clinical practice in recent years has provided convincing data that for patients with hepatocellular carcinoma whose hepatitis B virus continues to replicate in the body, routine postoperative antiviral therapy can greatly improve the survival rate and survival time of patients with hepatocellular carcinoma, as well as the quality of life and quality of life. Therefore, it is necessary for patients with hepatocellular carcinoma with chronic hepatitis B as background to start antiviral therapy immediately after performing hepatocellular carcinoma surgery. In fact, antiviral therapy should not stay “after the fact”, but should be significantly “port forward”. This forward movement includes: first, early detection of hepatitis B virus infection, and timely and effective antiviral treatment for patients with indications; second, if a person with hepatitis B virus infection is not known until cirrhosis is detected because of a delay in diagnosis, antiviral treatment should be given immediately regardless of whether the hepatitis B virus can be detected in the body; third, as soon as hepatitis B virus infection is detected in association with hepatocellular carcinoma, regardless of the treatment to be received. Third, as long as hepatitis B virus infection is found to be associated with liver cancer, antiviral treatment should be started immediately regardless of the means of treatment for liver cancer, rather than waiting for the treatment of liver cancer before antiviral treatment.